Lupin Q1 FY27 Results: Profit Jumps 16%, Sales Cross ₹8,200 Crore as India and North America Drive Strong Growth
India’s pharmaceutical major Lupin Limited started FY27 on a strong note, reporting robust revenue growth, expanding operating margins, and continued momentum across its India and North American businesses. The company’s Q1 FY27 investor presentation highlights record operating performance supported by new product launches, regulatory approvals, innovation, and a healthy global pipeline.
With double-digit growth across key markets, a strong complex generics pipeline, and continued investments in biosimilars and specialty medicines, Lupin appears well-positioned for sustained long-term growth.
Q1 FY27 Financial Highlights
Lupin delivered another quarter of healthy growth across revenue and profitability.
| Particular | Q1 FY27 | YoY Growth |
|---|---|---|
| Net Sales | ₹8,217 crore | 33% |
| EBITDA | ₹2,464 crore | 50% |
| EBITDA Margin | 30.0% | Up from 26.6% |
| Net Income | ₹1,415 crore | 16% |
| PAT Margin | 17.2% | Improved |
The company achieved one of its strongest quarterly EBITDA margins in recent years, reflecting better product mix, operating leverage, and disciplined cost management.
Geographic Growth Remains Broad-Based
Lupin witnessed growth across almost every major geography.
| Market | Q1 FY27 Revenue | YoY Growth |
|---|---|---|
| North America | ₹3,591 crore | 43% |
| India | ₹2,380 crore | 14% |
| EMEA | ₹1,034 crore | 65% |
| Latin America | ₹298 crore | 71% |
| Rest of World | ₹337 crore | 69% |
| API | ₹264 crore | 9% |
| APAC | ₹314 crore | Flat |
North America remained the largest contributor, accounting for nearly 42% of total revenue, while India contributed around 29%.
India Business Continues to Outperform the Market
Lupin’s domestic formulations business continued to grow faster than the Indian Pharmaceutical Market (IPM).
Key Highlights
- India business grew 13.9% YoY
- Prescription (Rx) business grew 15.1%
- Anti-diabetes business expanded 31.8%
- Chronic portfolio grew 21.5%
- Chronic therapies now contribute nearly 67% of India sales
- Seven new products launched during Q1
- More than 20 product launches planned during FY27
The company also strengthened its digital healthcare initiatives by onboarding nearly 10,000 cardiac patients through digital platforms while its diagnostics business served over 7 lakh patients during the quarter.
North America Continues to Power Growth
The U.S. business remained Lupin’s biggest growth engine.
Major highlights include:
- Revenue increased 43% YoY
- Three new products launched during Q1
- More than 15 launches planned during FY27
- Lupin remains the third-largest generic company in the U.S. by prescriptions.
- Leadership maintained in 112 products
- Number one market position in 56 products
The company continues to invest heavily in:
- Complex generics
- Inhalation therapies
- Injectable products
- Biosimilars
- Specialty medicines
Management plans to file over 15 ANDAs during FY27 while targeting more than 100 new product launches by FY31.
Strong Product Pipeline and Regulatory Progress
Lupin reported several important regulatory milestones during the quarter.
Major approvals and launches included:
- European approval to expand NaMuscla® for children aged 6–17 years.
- Approval in China for Oseltamivir Phosphate Oral Suspension, marking Lupin’s entry into the Chinese market through its partnership with Yabao Pharmaceuticals.
- Launch of Luforbec® in Spain through a strategic partnership.
- Phase 1a data for oncology candidate LNP8701 (SOS1 inhibitor) accepted for presentation at ASCO 2026.
On the manufacturing front:
- Nagpur Units I & II received regulatory approvals.
- Ankleshwar facility received CDSCO approval.
- Ankleshwar and Somerset facilities obtained favorable inspection outcomes.
- Remediation work continues at Pithampur Unit II.
India Strategy Focuses on Chronic Care Leadership
Lupin outlined several initiatives to sustain long-term growth in India.
These include:
- Expanding chronic therapies to nearly 70% of domestic sales by FY31
- Dedicated division for Semaglutide-based therapies
- Building innovative product partnerships
- Expanding consumer healthcare
- Growing diagnostics and digital health services
- Increasing penetration into extra-urban and hospital markets
The company also continues to evaluate licensing opportunities and acquisitions to strengthen its branded portfolio.
Innovation Remains a Core Growth Driver
Research and development continues to receive significant investment.
Q1 FY27 R&D Highlights
- R&D expenditure stood at ₹608 crore
- R&D represented 7.4% of sales
Lupin’s long-term innovation roadmap includes:
- 20 complex generic launches by 2028
- Five biosimilar filings in regulated markets
- Ten novel complex products for India
- Expansion across inhalation, injectables, ophthalmics, peptides, and biologics
Manufacturing Quality Continues to Improve
Quality remains one of Lupin’s strategic priorities.
Over the last year, several manufacturing sites completed regulatory inspections, including:
- Nagpur
- Goa
- Aurangabad
- Pune Biotech
- Somerset
- Ankleshwar
The company continues to strengthen digital quality systems while participating in global quality maturity initiatives.
Sustainability Becomes a Competitive Advantage
Lupin continues to receive global recognition for its ESG initiatives.
Major Sustainability Achievements
- Ranked No. 1 globally in Pharma in S&P Global ESG Ratings
- ESG Score improved to 91/100
- Included in the Dow Jones Best-in-Class World Index
- Featured in TIME World’s Most Sustainable Companies 2026
- Five consecutive years of water positivity
- Renewable energy contributes 48% of power consumption
- Approximately 41% reduction in greenhouse gas emissions versus FY23 baseline
The company also reported progress across diversity, supplier sustainability, employee volunteering, and community healthcare initiatives.
Long-Term Growth Strategy Remains Intact
Lupin’s strategy continues to focus on five key pillars:
- Expanding leadership in chronic therapies in India
- Growing complex generics in the U.S.
- Building biosimilar capabilities
- Investing in innovation-led specialty medicines
- Maintaining best-in-class manufacturing quality and ESG standards
Management believes these initiatives will support sustainable revenue growth while improving profitability over the coming years.
Lupin has entered FY27 with strong business momentum. Double-digit revenue growth, a healthy 30% EBITDA margin, continued product launches, expanding regulatory approvals, and a robust innovation pipeline demonstrate the company’s operational strength.
With leadership positions in India and the U.S., increasing investments in complex generics and biosimilars, and global recognition for sustainability, Lupin appears well-positioned to capitalize on long-term opportunities across the pharmaceutical industry.